Pharvaris (NASDAQ:PHVS) Price Target Cut to $34.00

Pharvaris (NASDAQ:PHVS) had its target price decreased by Morgan Stanley from $35.00 to $34.00 in a report published on Monday morning, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Other research analysts have also recently issued research reports about the stock. JMP Securities raised their price target on shares of Pharvaris from $49.00 to $50.00 and gave the stock a market outperform rating in a research note on Thursday, April 11th. Wedbush restated an outperform rating and set a $35.00 price target on shares of Pharvaris in a research note on Thursday, April 11th.

Pharvaris Stock Performance

Shares of PHVS opened at $20.15 on Monday. Pharvaris has a 12 month low of $7.93 and a 12 month high of $33.00. The company has a 50-day moving average price of $24.77 and a two-hundred day moving average price of $23.30.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. venBio Partners LLC raised its stake in shares of Pharvaris by 15.4% in the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock valued at $137,992,000 after acquiring an additional 654,832 shares during the last quarter. Viking Global Investors LP raised its stake in shares of Pharvaris by 13.2% in the fourth quarter. Viking Global Investors LP now owns 3,656,923 shares of the company’s stock valued at $102,577,000 after acquiring an additional 425,000 shares during the last quarter. Novo Holdings A S raised its stake in shares of Pharvaris by 15.8% in the fourth quarter. Novo Holdings A S now owns 1,539,325 shares of the company’s stock valued at $43,178,000 after acquiring an additional 210,000 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pharvaris in the fourth quarter valued at approximately $23,638,000. Finally, Commodore Capital LP acquired a new stake in shares of Pharvaris in the fourth quarter valued at approximately $22,440,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).